MEDSCI303 | MEDSCI303 Pharmacy Exam 4
Version 3 | Questions with Correct Answers and
Expert Explanation for Each Question | Rajiv
Gandhi University of Health Sciences
1. A patient with suspected multidrug-resistant (MDR) Pseudomonas aeruginosa
bacteremia is started on combination therapy. Which of the following rationale best
supports the use of double-coverage in this high-risk clinical scenario?
A. To provide synergy and increase the probability of at least one agent being active
against the isolate.
B. To decrease the risk of infusion-related reactions associated with high-dose
monotherapy.
C. To allow for lower doses of each individual agent, thereby reducing the risk of
nephrotoxicity.
D. To intentionally induce the AmpC beta-lactamase enzyme to make the pathogen
more susceptible to carbapenems.
Correct Answer: A
Expert Explanation: Double-coverage for Pseudomonas aeruginosa is primarily
employed to ensure that at least one antibiotic is active while awaiting susceptibility
results. This strategy is particularly vital in patients with high-risk features or in
institutions with high resistance rates. Combination therapy can also provide
,synergistic killing, which may improve clinical outcomes in critically ill patients. It
helps prevent the development of further resistance by targeting different bacterial
pathways simultaneously. Clinical judgment must balance these benefits against the
potential for increased drug toxicity or side effects.
2. Which pharmacodynamic parameter is the most important predictor of efficacy for
vancomycin when treating serious MRSA infections, such as endocarditis or
osteomyelitis?
A. The 24-hour Area Under the Curve to MIC ratio (AUC24/MIC) of 400 to 600
B. Percentage of the dosing interval that the free drug concentration remains above
the MIC (%fT > MIC) > 40%
C. Peak concentration to Minimum Inhibitory Concentration ratio (Cmax/MIC) > 10
D. Total time the concentration stays above the Minimum Bactericidal
Concentration (T > MBC)
Correct Answer: A
Expert Explanation: Current clinical guidelines emphasize the use of AUC-guided
monitoring for vancomycin to optimize efficacy and minimize nephrotoxicity. An
AUC24/MIC ratio between 400 and 600 is considered the therapeutic target for
invasive MRSA infections. Relying solely on trough concentrations is no longer
recommended as it often leads to sub-optimal dosing or unnecessary toxicity.
,Pharmacokinetic modeling or Bayesian software is frequently used to estimate
these values in clinical practice. This shift in practice reflects a more sophisticated
understanding of vancomycin’s concentration-time profile.
3. A patient being treated for a complex intra-abdominal infection develops significant
eosinophilia and acute kidney injury after 3 weeks of Daptomycin therapy. What is the
most likely adverse event occurring?
A. Drug-induced aseptic meningitis
B. Acute interstitial nephritis or DRESS syndrome
C. Daptomycin-induced rhabdomyolysis leading to renal failure
D. Inactivation of Daptomycin by pulmonary surfactant
Correct Answer: B
Expert Explanation: Daptomycin is known to cause various hypersensitivity
reactions, including eosinophilic pneumonia and acute interstitial nephritis. The
presence of eosinophilia along with sudden renal decline strongly suggests an
immune-mediated response like AIN or DRESS. While rhabdomyolysis is a common
side effect monitored via CPK levels, it usually presents with muscle pain.
Daptomycin should be discontinued immediately if such systemic hypersensitivity is
suspected to prevent further organ damage. Clinicians must distinguish between
metabolic side effects and rare but serious allergic complications.
, 4. Which statement accurately describes the therapeutic challenge of using
Ceftazidime-avibactam in a patient with a Carbapenem-Resistant Enterobacteriaceae
(CRE) infection?
A. It is highly effective against New Delhi Metallo-beta-lactamase (NDM) producing
strains.
B. It lacks activity against Class B carbapenemases but covers Class A (KPC) and
Class D (OXA-48).
C. It requires the co-administration of a glycopeptide to stabilize the avibactam
component.
D. It is primarily used for its ability to penetrate the blood-brain barrier in neonatal
meningitis.
Correct Answer: B
Expert Explanation: Ceftazidime-avibactam is a potent agent against CRE strains
that produce KPC or OXA-48 carbapenemases. However, it is not active against
Metallo-beta-lactamases (MBLs) like NDM or VIM, which belong to Ambler Class B.
In cases of MBL-producing infections, Aztreonam is often combined with
Ceftazidime-avibactam to provide coverage. Understanding the specific molecular
mechanism of resistance is crucial for selecting the appropriate anti-infective
therapy. Misidentifying the carbapenemase type can lead to treatment failure and
increased mortality.
Version 3 | Questions with Correct Answers and
Expert Explanation for Each Question | Rajiv
Gandhi University of Health Sciences
1. A patient with suspected multidrug-resistant (MDR) Pseudomonas aeruginosa
bacteremia is started on combination therapy. Which of the following rationale best
supports the use of double-coverage in this high-risk clinical scenario?
A. To provide synergy and increase the probability of at least one agent being active
against the isolate.
B. To decrease the risk of infusion-related reactions associated with high-dose
monotherapy.
C. To allow for lower doses of each individual agent, thereby reducing the risk of
nephrotoxicity.
D. To intentionally induce the AmpC beta-lactamase enzyme to make the pathogen
more susceptible to carbapenems.
Correct Answer: A
Expert Explanation: Double-coverage for Pseudomonas aeruginosa is primarily
employed to ensure that at least one antibiotic is active while awaiting susceptibility
results. This strategy is particularly vital in patients with high-risk features or in
institutions with high resistance rates. Combination therapy can also provide
,synergistic killing, which may improve clinical outcomes in critically ill patients. It
helps prevent the development of further resistance by targeting different bacterial
pathways simultaneously. Clinical judgment must balance these benefits against the
potential for increased drug toxicity or side effects.
2. Which pharmacodynamic parameter is the most important predictor of efficacy for
vancomycin when treating serious MRSA infections, such as endocarditis or
osteomyelitis?
A. The 24-hour Area Under the Curve to MIC ratio (AUC24/MIC) of 400 to 600
B. Percentage of the dosing interval that the free drug concentration remains above
the MIC (%fT > MIC) > 40%
C. Peak concentration to Minimum Inhibitory Concentration ratio (Cmax/MIC) > 10
D. Total time the concentration stays above the Minimum Bactericidal
Concentration (T > MBC)
Correct Answer: A
Expert Explanation: Current clinical guidelines emphasize the use of AUC-guided
monitoring for vancomycin to optimize efficacy and minimize nephrotoxicity. An
AUC24/MIC ratio between 400 and 600 is considered the therapeutic target for
invasive MRSA infections. Relying solely on trough concentrations is no longer
recommended as it often leads to sub-optimal dosing or unnecessary toxicity.
,Pharmacokinetic modeling or Bayesian software is frequently used to estimate
these values in clinical practice. This shift in practice reflects a more sophisticated
understanding of vancomycin’s concentration-time profile.
3. A patient being treated for a complex intra-abdominal infection develops significant
eosinophilia and acute kidney injury after 3 weeks of Daptomycin therapy. What is the
most likely adverse event occurring?
A. Drug-induced aseptic meningitis
B. Acute interstitial nephritis or DRESS syndrome
C. Daptomycin-induced rhabdomyolysis leading to renal failure
D. Inactivation of Daptomycin by pulmonary surfactant
Correct Answer: B
Expert Explanation: Daptomycin is known to cause various hypersensitivity
reactions, including eosinophilic pneumonia and acute interstitial nephritis. The
presence of eosinophilia along with sudden renal decline strongly suggests an
immune-mediated response like AIN or DRESS. While rhabdomyolysis is a common
side effect monitored via CPK levels, it usually presents with muscle pain.
Daptomycin should be discontinued immediately if such systemic hypersensitivity is
suspected to prevent further organ damage. Clinicians must distinguish between
metabolic side effects and rare but serious allergic complications.
, 4. Which statement accurately describes the therapeutic challenge of using
Ceftazidime-avibactam in a patient with a Carbapenem-Resistant Enterobacteriaceae
(CRE) infection?
A. It is highly effective against New Delhi Metallo-beta-lactamase (NDM) producing
strains.
B. It lacks activity against Class B carbapenemases but covers Class A (KPC) and
Class D (OXA-48).
C. It requires the co-administration of a glycopeptide to stabilize the avibactam
component.
D. It is primarily used for its ability to penetrate the blood-brain barrier in neonatal
meningitis.
Correct Answer: B
Expert Explanation: Ceftazidime-avibactam is a potent agent against CRE strains
that produce KPC or OXA-48 carbapenemases. However, it is not active against
Metallo-beta-lactamases (MBLs) like NDM or VIM, which belong to Ambler Class B.
In cases of MBL-producing infections, Aztreonam is often combined with
Ceftazidime-avibactam to provide coverage. Understanding the specific molecular
mechanism of resistance is crucial for selecting the appropriate anti-infective
therapy. Misidentifying the carbapenemase type can lead to treatment failure and
increased mortality.
